Dainippon Sumitomo Pharma Revises Domestic Development Plan of AC-5216, an Antianxiety/antidepressant Agent
October 22, 2014     Japanese 
  JCN 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
 
Dainippon Sumitomo Pharma Revises Domestic Development Plan of AC-5216, an Antianxiety/antidepressant Agent - JCN Newswire
Share:
Dainippon Sumitomo Pharma Revises Domestic Development Plan of AC-5216, an Antianxiety/antidepressant Agent

Osaka, Nov 28, 2006 - (JCN Newswire) - Dainippon Sumitomo Pharma Co., Ltd. ('DSP') today announced it has decided to discontinue its already initiated Phase II clinical trial in Japan and revise the domestic development plan of AC-5216, an investigational compound discovered by DSP which is in development for the treatment of depression and anxiety disorders.

DSP has been conducting a Phase II clinical trial in Japan for the treatment of Panic Disorder. Novartis, which has been granted exclusive global development rights outside Japan, Korea, China and Taiwan, has been conducting a Phase II clinical trial in North America for the treatment of Generalized Anxiety Disorder.

After review of the clinical data obtained to date by both DSP and Novartis, DSP has decided to discontinue the Phase II clinical trial in Japan and revise the development plan for this compound including optimal dose.

DSP and Novartis are currently discussing future development plan.

About Dainippon Sumitomo

Dainippon Pharmaceutical and Sumitomo Pharmaceuticals merged on October 1, 2005, to create Dainippon Sumitomo Pharma (TSE: 4506), a new corporation committed to serving the social good through research and development programs designed to empower people to lead fuller, healthier lives. Among the capabilities being deployed to create new value for shareholders and customers alike are research and development programs that excel in sophistication and creativity, quality and production systems that ensure the enduring trust of our customers, some of Japan's most developed sales and marketing resources, and an unmatched ability to provide reliable data to medical decision-makers. For more information, please visit www.ds-pharma.co.jp

Contact:

Dainippon Sumitomo Pharma Co., Ltd.
Public Relations Department
Tel: +81-6-6203-1407
Fax: +81-6-6203-5548

 


Nov 28, 2006
Source: Dainippon Sumitomo

Dainippon Sumitomo (TSE: 4506) (U.S: DNPUF)

From the Japan Corporate News Network
http://www.japancorp.net
Topic: Press release summary
View more news from these Sectors: Drugs & OTC, Drugs & OTC


 
CSR Report Download
Annual Reports

  More >>    
Most Popular


About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)